ArticleInternational journal of surgery (London, England)2026
Ultrasound-mediated targeted micro/nanobubbles: breaking new boundaries in precision tumor therapy.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumors pose a public health challenge due to escalating incidence and mortality. Traditional treatments suffer from poor target specificity between healthy and tumor tissues, resulting in severe side effects. Immunotherapy is a pivotal advancement, but it faces poor tumor penetration, low targeting efficiency, inadequate drug delivery, immune evasion, and drug resistance. To overcome these challenges, ultrasound-mediated targeted micro/nanobubbles (UMT-MNBs) emerge, which is a noninvasive, highly targeted, and nonviral vector novel therapeutic method for malignant tumors. This approach overcomes drug resistance and facilitates the targeted release of therapeutic molecules. Concurrently, MNBs activate the immune system, enhance immune cell filtration, suppress tumor angiogenesis, and induce immunogenic cell death (ICD). UMT-MNBs demonstrate synergistic potential with conventional therapies, showcasing substantial clinical promise. This review presents recent advances in UMT-MNBs for drug/gene delivery, hypoxia modulation, resistance mitigation, immune activation/regulation, and penetration of blood-brain barrier. It also introduces UMT-MNBs in combinatorial regimens, including chemo, radio, photothermal, photodynamic, and sonodynamic therapies, to reduce dosage, improve efficacy, and minimize toxicity, thereby advancing precision medicine in oncology. Finally, future research on UMT-MNBs is discussed. It is necessary to focus on optimizing ultrasound parameters, emphasizing surface functionalization of MNBs, elucidating the mechanisms of immune activation and regulation, and exploring multimodal combined treatment strategies. Our findings provide new insights into the visualization and real-time regulation capabilities of UMT-MNBs, driving the application of immunotherapy and combination therapies, opening new directions for targeted therapy, and facilitating breakthrough progress in cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.